Abstract
BackgroundIn the Phase 3 EXPAND study, siponimod reduced the Neurostatus-EDSS-measured risk of 3/6-month (M) confirmed disability progression versus placebo by 21%/26%, with more pronounced effects (31%/37%) in active SPMS (aSPMS)....
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have